Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 12OTHER 11NIH 1NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Lung Neoplasms 1

Interventions

Gemcitabine 18Cisplatin 14Paclitaxel 9Vinblastine 7Methotrexate 7Radiotherapy 6Doxorubicin 6Carboplatin 6Fluorouracil 4Surgical Procedures, Operative 3Mitomycin 3Filgrastim 3BCG Vaccine 3Gefitinib 2Docetaxel 2Cystectomy 2valrubicin 1rubitecan 1romidepsin 1piritrexim 1merphos 1lonafarnib 1durvalumab 1avelumab 1atezolizumab 1Watchful Waiting 1Urination 1Transurethral Resection of Bladder 1Taxes 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Urinary Bladder Neoplasms × avelumab × Clear all
NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

SWOG Cancer Research Network

Phase 2 Terminated
6 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡